Cargando…
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958277/ https://www.ncbi.nlm.nih.gov/pubmed/36791668 http://dx.doi.org/10.1016/j.esmoop.2023.100879 |
| _version_ | 1784894987889016832 |
|---|---|
| author | Moliner, L. Spurgeon, L. Califano, R. |
| author_facet | Moliner, L. Spurgeon, L. Califano, R. |
| author_sort | Moliner, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9958277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99582772023-02-26 Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? Moliner, L. Spurgeon, L. Califano, R. ESMO Open Editorial Elsevier 2023-02-13 /pmc/articles/PMC9958277/ /pubmed/36791668 http://dx.doi.org/10.1016/j.esmoop.2023.100879 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Editorial Moliner, L. Spurgeon, L. Califano, R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title | Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title_full | Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title_fullStr | Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title_full_unstemmed | Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title_short | Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? |
| title_sort | controversies in nsclc: which second-line strategy after chemo-immunotherapy? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958277/ https://www.ncbi.nlm.nih.gov/pubmed/36791668 http://dx.doi.org/10.1016/j.esmoop.2023.100879 |
| work_keys_str_mv | AT molinerl controversiesinnsclcwhichsecondlinestrategyafterchemoimmunotherapy AT spurgeonl controversiesinnsclcwhichsecondlinestrategyafterchemoimmunotherapy AT califanor controversiesinnsclcwhichsecondlinestrategyafterchemoimmunotherapy |